Key result
Moxonidine in combination therapy demonstrated high antihypertensive efficacy, safety, and positive metabolic effects in a postmenopausal woman with abdominal obesity.
Why the study?
Hypertension in postmenopausal women frequently clusters with metabolic syndrome components, requiring therapeutic approaches that effectively and safely address multiple targets simultaneously.
Does moxonidine in combination therapy improve blood pressure and metabolic parameters in a postmenopausal obese woman with hypertension?
Case Report (n=1)
Does moxonidine in combination therapy improve blood pressure and metabolic parameters in a postmenopausal obese woman with hypertension?
Moxonidine may be an effective and safe component of combination antihypertensive therapy for postmenopausal women with abdominal obesity and metabolic syndrome.
Moxonidine combination may aid BP and metabolic control in obese postmenopausal hypertension; hypothesis-generating, needs RCT confirmation.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Остроумова et al. (2020) conducted a case report in Hypertension and abdominal obesity in postmenopause (n=1). Moxonidine in combination therapy was evaluated on Antihypertensive activity, safety, and metabolic effects. Moxonidine in combination therapy demonstrated high antihypertensive efficacy, safety, and positive metabolic effects in a postmenopausal woman with abdominal obesity.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: